Ann: Alterity to present at MST Access Investor Conference, page-3

Would also be nice, unless a deal or deals are immanent and they purposely want to keep it hush-hush, that they made some mention of PBT2 and it's efficacy in the Antibiotic Resistance Market which could also be discussed. Absolutely, no mention of this extremely lucrative opportunity!? I realize that ATHE434 has been Stamler's baby and focus since he joined the Company but sometimes you have to seize the moment and grab the brass ring, especially when soliciting potential investors or partners. C'mon man! Maybe Pivalde is available to join the good doctor on the broadcast. We all know how he can inspire, light a fire, market, and SELL a life-saving drug. ATHE's management has always been unable to do this as they lack charisma, marketing/merchandizing, and sales skills. GLTA shareholders...